ATE235890T1 - Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr - Google Patents

Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr

Info

Publication number
ATE235890T1
ATE235890T1 AT98904760T AT98904760T ATE235890T1 AT E235890 T1 ATE235890 T1 AT E235890T1 AT 98904760 T AT98904760 T AT 98904760T AT 98904760 T AT98904760 T AT 98904760T AT E235890 T1 ATE235890 T1 AT E235890T1
Authority
AT
Austria
Prior art keywords
microparticles
immune defense
stimulate immune
adsorbed antigen
antigen
Prior art date
Application number
AT98904760T
Other languages
English (en)
Inventor
Derek O'hagan
Nest Gary Van
Gary S Ott
John Barackman
Jina Kazzaz
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE235890T1 publication Critical patent/ATE235890T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT98904760T 1997-01-30 1998-01-29 Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr ATE235890T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3631697P 1997-01-30 1997-01-30
US6974997P 1997-12-16 1997-12-16
PCT/US1998/001738 WO1998033487A1 (en) 1997-01-30 1998-01-29 Use of microparticles with adsorbed antigen to stimulate immune responses

Publications (1)

Publication Number Publication Date
ATE235890T1 true ATE235890T1 (de) 2003-04-15

Family

ID=26713053

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98904760T ATE235890T1 (de) 1997-01-30 1998-01-29 Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr

Country Status (13)

Country Link
US (2) US7597908B2 (de)
EP (1) EP0991403B1 (de)
JP (2) JP5037747B2 (de)
AT (1) ATE235890T1 (de)
AU (1) AU747577B2 (de)
CA (1) CA2279204C (de)
DE (1) DE69812941T2 (de)
DK (1) DK0991403T3 (de)
ES (1) ES2195317T3 (de)
HK (1) HK1023507A1 (de)
NZ (1) NZ337054A (de)
PT (1) PT991403E (de)
WO (1) WO1998033487A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100372375B1 (ko) 1993-12-23 2003-04-21 머클한스피터 면역반응의강화방법
US20040202680A1 (en) * 1997-01-30 2004-10-14 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
ATE321535T1 (de) * 1998-07-29 2006-04-15 Chiron Corp Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
EP1574210B1 (de) 1999-02-26 2016-04-06 Novartis Vaccines and Diagnostics, Inc. Mikroemulsionen mit adsorbierten Makromolekülen
JP2002538195A (ja) * 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
US7713739B1 (en) 2000-11-17 2010-05-11 Novartis Vaccines And Diagnostics, Inc. Microparticle-based transfection and activation of dendritic cells
GB0000001D0 (en) * 2000-01-05 2000-02-23 Du Pont Uk Pharmaceutical compositions and their preparation
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
GB0006770D0 (en) * 2000-03-22 2000-05-10 Secr Defence Vaccine composition
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
AU2001294898B2 (en) * 2000-09-28 2006-02-02 Novartis Vaccines And Diagnostic Inc. Microparticle compositions and methods for the manufacture thereof
US20030138453A1 (en) * 2000-09-28 2003-07-24 O'hagan Derek Microparticles for delivery of heterologous nucleic acids
US6887857B2 (en) 2001-04-27 2005-05-03 Scimed Life Systems, Inc. Microparticle protection of therapeutic agents
DE10125731A1 (de) * 2001-05-17 2003-03-06 A I D Autoimmun Diagnostika Gm Darreichungsform von immunologischen Wirkstoffen
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
US7501134B2 (en) 2002-02-20 2009-03-10 Novartis Vaccines And Diagnostics, Inc. Microparticles with adsorbed polypeptide-containing molecules
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
US20060110736A1 (en) * 2002-10-07 2006-05-25 John Donnelly Hiv vaccine formulations
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006520746A (ja) 2002-12-27 2006-09-14 カイロン コーポレイション リン脂質を含む免疫原性組成物
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
EP1631264B8 (de) 2003-06-02 2017-05-24 GlaxoSmithKline Biologicals SA Immunogene, auf mikropartikel basierende zusammensetzungen, die aus einem adsorbierten toxoid und einem polysaccharid enthaltenden antigen bestehen
FR2859909B1 (fr) * 2003-09-22 2007-09-07 Biomerieux Sa Procede de preparation de microparticules bioresorbables, microparticules obtenues et utilisation
US9107813B2 (en) 2004-11-15 2015-08-18 Derek T. O'Hagan Immunogenic compositions containing anthrax antigen, biodegradable polymer microparticles, and polynucleotide-containing immunological adjuvant
JP2009514841A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 粒子状アジュバントと免疫増強物質との組合せを含むインフルエンザワクチン
FR2893254B1 (fr) * 2005-11-14 2007-12-21 Biomerieux Sa Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral et son utilisation prophylactique, therapeutique et diagnostique.
CA2643322C (en) 2006-02-24 2015-07-21 Novartis Ag Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions
EP3067048B1 (de) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Zusammensetzungen zur induzierung von immunreaktionen
JP2013532008A (ja) 2010-05-28 2013-08-15 テトリス オンライン インコーポレイテッド 対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
CN103796639B (zh) 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
SG10201605512WA (en) 2011-07-06 2016-09-29 Novartis Ag Oil-in-water emulsions that contain nucleic acids
WO2013028738A1 (en) 2011-08-22 2013-02-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
US9782520B2 (en) 2011-09-26 2017-10-10 BioSpheres, Inc. Reduction of implant infection via tunable stimulation of localized adaptive immune response
WO2019169370A1 (en) * 2018-03-02 2019-09-06 University Of The Sciences Polymer compositions for storage and release of polypeptides
EP3581201A1 (de) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 polypeptide und verwendungen davon

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4413057A (en) * 1980-04-14 1983-11-01 Merck & Co., Inc. Group B streptococcal capsular polysaccharides
US4534996A (en) * 1981-03-30 1985-08-13 California Institute Of Technology Hybrid microspheres
JPS6150378A (ja) * 1984-08-20 1986-03-12 Mitsui Toatsu Chem Inc 非晶質太陽電池の製法
US5151266A (en) * 1985-08-20 1992-09-29 Neorx Corporation Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies
US5151225A (en) 1989-05-01 1992-09-29 Hoover Treated Wood Products, Inc. Flame retardant composition and method for treating wood
EP0474727B1 (de) * 1989-05-19 1997-07-23 Genentech, Inc. Her2 extrazellulare domäne
US5010183A (en) * 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
AU645760B2 (en) 1989-08-04 1994-01-27 Berlex Laboratories, Inc. C-erbb-2 external domain: GP75
CA2113720A1 (en) * 1991-07-25 1993-02-04 Syamal Raychaudhuri Induction of cytotoxic t-lymphocyte responses
EP0615453B1 (de) * 1991-11-29 1997-05-14 Chiron Viagene, Inc. Immuntherapeutische vektorkonstrukte gegen krebs
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
FR2695563B1 (fr) * 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US5928647A (en) * 1993-01-11 1999-07-27 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US5801005A (en) * 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
GB9311454D0 (en) * 1993-06-03 1993-07-21 Agricultural & Food Res Pharmaceutical compositions
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US5902565A (en) * 1993-12-24 1999-05-11 Csl Limited Spray dried vaccine preparation comprising aluminium adsorbed immunogens
WO1995024929A2 (en) 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
AU2517895A (en) 1994-05-20 1995-12-18 Microgenesys, Inc. Hiv polyprotein immunogens
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5660854A (en) * 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5827531A (en) * 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
WO1996020698A2 (en) * 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
EP0812358A1 (de) * 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptide verwendbar als immunotherapeutischen mitteln und verfahren zur bereitung von polypeptiden
US5714354A (en) * 1995-06-06 1998-02-03 American Home Products Corporation Alcohol-free pneumococcal polysaccharide purification process
GB9514285D0 (en) * 1995-07-13 1995-09-13 Univ Nottingham Polymeric lamellar substrate particles for drug delivery
US5630922A (en) * 1995-12-26 1997-05-20 Ppg Industries, Inc. Electrodepositable coating composition containing diorganotin dicarboxylates
JP2002515734A (ja) 1996-01-02 2002-05-28 カイロン コーポレイション 遺伝子改変された樹状細胞により媒介される免疫刺激
US5855913A (en) * 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
GB9619002D0 (en) 1996-09-11 1996-10-23 Oxford Biosciences Ltd Particle delivery
US5783567A (en) * 1997-01-22 1998-07-21 Pangaea Pharmaceuticals, Inc. Microparticles for delivery of nucleic acid
ES2195317T3 (es) 1997-01-30 2003-12-01 Chiron Corp Uso de microparticulas con antigeno adsorbido para estimular respuestas inmunitarias.
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6086901A (en) * 1997-12-16 2000-07-11 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US7060284B1 (en) 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
AU2001294898B2 (en) * 2000-09-28 2006-02-02 Novartis Vaccines And Diagnostic Inc. Microparticle compositions and methods for the manufacture thereof
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
US20100021548A1 (en) 2010-01-28
ES2195317T3 (es) 2003-12-01
HK1023507A1 (en) 2000-09-15
WO1998033487A1 (en) 1998-08-06
AU6255798A (en) 1998-08-25
PT991403E (pt) 2003-08-29
EP0991403A1 (de) 2000-04-12
CA2279204C (en) 2005-11-15
JP2001511148A (ja) 2001-08-07
DK0991403T3 (da) 2003-07-28
EP0991403B1 (de) 2003-04-02
NZ337054A (en) 2001-03-30
JP5037747B2 (ja) 2012-10-03
DE69812941D1 (de) 2003-05-15
US20030049298A1 (en) 2003-03-13
US7597908B2 (en) 2009-10-06
DE69812941T2 (de) 2004-02-05
JP2009102338A (ja) 2009-05-14
AU747577B2 (en) 2002-05-16
CA2279204A1 (en) 1998-08-06

Similar Documents

Publication Publication Date Title
DE69812941D1 (de) Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
DE69112508T2 (de) Phosphore mit verbesserter lichtausbeute und daraus hergestellte lampen.
KR900700607A (ko) 면역학적 주효체 세포 활성화 및 화학적 인력을 유발하는 단백질
DE3884190D1 (de) Behandlung von unterirdischen Formationen mit spät reagierenden Quervernetzenden Gelen.
DE69720190T2 (de) Implantierbares system mit verzögerter freisetzung von leuprolid
DE3882286D1 (de) Temperierbeschleuniger und seine verwendung.
DE69411692D1 (de) Mittel zur Förderung der Proliferationen von Bifidobacterium
DE69826079D1 (de) Lokalisator von elektrisch leitenden objekten
BR8902170A (pt) Aparelho de iluminacao e refletor
DE68906822D1 (de) Spulentraeger mit heizspule.
NO902696D0 (no) Ny familie av modifiserte hoeyaffinitetsantistoff for kreftbehandling.
DE69034090D1 (de) Halbleitervorrichtung zur Detektion oder Emission von Magnetfeldlinien oder Licht
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
ATE330620T1 (de) Verwendung von midkin oder von anti-midkin antikörper
DE69008535D1 (de) Humane antigammainterferonantikörper, welche detektiert und geklärt sind mit verwendung von synthetischen peptiden.
DE68918934D1 (de) Einrichtung zur Beleuchtung und Heizung.
DE3876213D1 (de) Dimerisierung von acrylnitril.
DE3763615D1 (de) Stosswellenquelle mit erhoehtem wirkungsgrad.
DE69632673D1 (de) Herzschrittmacher mit Detektion der evozierten Reaktion
DE69836056D1 (de) Prozessor mit verringerter Zahl von bedingten Befehlen
DE69103501T2 (de) Gerät zur mehrfachen kontrolle von innenabmessungen.
DE68910529D1 (de) Von mikrowellen angetriebene heizkammer.
DE10080481D2 (de) Spezifische IgY-Eidotterantikörper, ihre Gewinnung und ihre Verwendung
DE69732497D1 (de) Bremsvorrichtung mit zone von kontrolierter zerbrechlichkeit
FI890183A0 (fi) Anordning foer roerelse i en roerformad ledning.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0991403

Country of ref document: EP